Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of age

Stage I of this study (NCT04142242) demonstrated the safety and immunogenicity of a booster dose of a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) and immune persistence 3 and 6–7 years after priming in older adults who received either quadrivalent meningococcal...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Corwin A. Robertson, Jeffry Jacqmein, Alexandre Selmani, Katherine Galarza, Philipp Oster
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Taylor & Francis Group 2024-12-01
Цуврал:	Human Vaccines & Immunotherapeutics
Нөхцлүүд:	Antibody persistence booster elderly immunogenicity MenACYW-TT booster quadrivalent meningococcal conjugate vaccine
Онлайн хандалт:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2426868
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!